Immunoglobulin News and Research

RSS

IBEC researchers discover new group of interacting partners for myelin-associated receptors

It's known that the development of neuronal diseases such as multiple sclerosis and Alzheimer's disease is connected with the levels of myelin - an insulating substance around nerve fibres - in the body, although the actual causes of these conditions remain unknown. Now researchers at IBEC have discovered a new group of interacting partners for myelin-associated receptors, which could shed light on the significance of imbalanced production or modifications of the substance.

12 Nov 2010

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

The 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) brings together leading allergists and immunologists from around the world.

12 Nov 2010

Hydroxychloroquine may reduce cardiac neonatal lupus in subsequent pregnancies: Research

Women with anti-SSA/Ro antibodies and a previous child who has heart block a condition where the electrical signal that makes the heart beat is damaged may potentially decrease their risk of delivering another child with life threatening heart disease by taking hydroxychloroquine (Plaquenil), according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

CSL Behring creates Interlaken Leadership Awards to support innovative immunoglobulin research

To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it has created the Interlaken Leadership Awards. This global awards program will provide monetary grants to advance medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurologic disorders.

29 Oct 2010

Talecris third quarter net revenue increases 2.8% to $407.0 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three and nine months ended September 30, 2010 and filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (SEC).

29 Oct 2010

Baxter third quarter net income increases 12% to $595 million

Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.

From Baxter International Inc. 21 Oct 2010

Pericytes regulate blood-brain barrier

While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.

15 Oct 2010

FDA approves Gamunex-C for primary immunodeficiency treatment

Talecris Biotherapeutics announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI).

15 Oct 2010

Scientists find pericytes regulate blood-brain barrier

14 Oct 2010

Vivaglobin therapy effective for patients with primary immunodeficiency

Vivaglobin (subcutaneous immunoglobulin [IgG]) (SCIg) is an effective and safe initial therapy for treatment-naive patients with primary immunodeficiency (PI) and may offer an attractive alternative to intravenous IgG (IVIg) therapy in the newly diagnosed, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies.

7 Oct 2010

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Privigen, the first and only 10% liquid intravenous immunoglobulin (IVIg) therapy stabilized with proline, is effective and well tolerated in patients with several primary and secondary immunodeficiencies, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies. Results also demonstrate that Privigen offers significant protection against infection.

7 Oct 2010

Hizentra therapy effective for primary immunodeficiency patients

Hizentra (IgPro20) provides primary immunodeficiency (PI) patients with a safe and effective alternative to other immunoglobulin therapies when given in equivalent doses, according to Phase III pivotal trial data presented today at the XIVth Meeting of the European Society for Immunodeficiencies (ESID).

7 Oct 2010

Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID

Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.

From Baxter International Inc. 6 Oct 2010

Crescendo Biologics successfully delivers triple knockout mice

Crescendo Biologics Limited today announces it has established a colony of engineered mice completely devoid of endogenous antibody polypeptides. The proprietary 'triple knockout' mice are believed to be unique and have the immunoglobulin heavy chain (IgH), kappa light chain and lambda light chain loci all functionally silenced by large-scale genomic deletion.

29 Sep 2010

GBS pathogen suppresses immune cell function in newborn infants: Research

Group B Streptococcus (GBS), a bacterial pathogen that causes sepsis and meningitis in newborn infants, is able to shut down immune cell function in order to promote its own survival, according to researchers at the University of California, San Diego School of Medicine and the Skaggs School of Pharmacy and Pharmaceutical Sciences.

27 Sep 2010

H1N1 influenza increases neurological complications in children: Study

A recent study by researchers at the University of Utah determined that the 2009 pandemic influenza A (H1N1) caused a higher rate of neurological complications in children than the seasonal flu. The most common complications observed were seizures and encephalopathy.

20 Sep 2010

RAB-1 monoclonal antibody study shows positive result for rabies

With the potential to save tens of thousands of lives each year, a new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India took an important step forward with positive results from a Phase 1 study. The recently completed study showed that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.

15 Sep 2010

Excelimmune presents positive results for HRPA therapy against MRSA infections

Excelimmune, Inc. announced positive results from preclinical studies evaluating the efficacy of its human recombinant polyclonal antibody (HRPA) therapy against infections caused by methicillin-resistant Staphylococcus aureus (MRSA).

14 Sep 2010

PPTA supports CMS' proposal for hospital outpatient reimbursement for plasma protein therapies

The Plasma Protein Therapeutics Association (PPTA) recommends that the Centers for Medicare and Medicaid Services (CMS) finalize its Proposed Rule regarding reimbursement to better ensure patient access to vital medicines in the hospital outpatient setting.

8 Sep 2010

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

Octapharma AG today announced the imminent start of the biggest ever study of an intravenous immunoglobulin preparation (IVIG) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

8 Sep 2010

Immunoglobulin News and Research

IBEC researchers discover new group of interacting partners for myelin-associated receptors

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

Hydroxychloroquine may reduce cardiac neonatal lupus in subsequent pregnancies: Research

CSL Behring creates Interlaken Leadership Awards to support innovative immunoglobulin research

Talecris third quarter net revenue increases 2.8% to $407.0 million

Baxter third quarter net income increases 12% to $595 million

Pericytes regulate blood-brain barrier

FDA approves Gamunex-C for primary immunodeficiency treatment

Scientists find pericytes regulate blood-brain barrier

Vivaglobin therapy effective for patients with primary immunodeficiency

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Hizentra therapy effective for primary immunodeficiency patients

Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID

Crescendo Biologics successfully delivers triple knockout mice

GBS pathogen suppresses immune cell function in newborn infants: Research

H1N1 influenza increases neurological complications in children: Study

RAB-1 monoclonal antibody study shows positive result for rabies

Excelimmune presents positive results for HRPA therapy against MRSA infections

PPTA supports CMS' proposal for hospital outpatient reimbursement for plasma protein therapies

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News